tence and increased health care costs in older adults with dementia in a managed care setting. Health status assessments completed at enrollment had the potential to identify enrollees at higher risk for nonadherent behaviors and poor health related outcomes. OBJECTIVE: To evaluate the effectiveness of risperidone long-acting injection (RLAI) treatment on personal and social functioning in patients with schizophrenia enrolled in the electronic-Schizophrenia Treatment Adherence Registry (e-STAR) from six countries (Canada, Czech Republic, Denmark, Netherlands, Slovakia, Sweden) that collected Personal and Social Performance (PSP) data. METHODS: e-STAR is an international, long-term, prospective, observational study of patients with schizophrenia who commence RLAI. Data are collected retrospectively for one year and prospectively every three months for two years. Personal and social functioning is measured using the PSP scale which evaluates four areas, socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviour. Pooled results presented are based on data from patients who have completed their six-month follow-up visit. RESULTS: To date, 1831 are enrolled in e-STAR from the six countries, 1232 patients who have been followed for at least 6 months are included in this analysis. Mean age was 38.4 Ϯ 12.5 years, 58.6% were male and mean time since diagnosis was 9.6 Ϯ 11.6 years. At 6 months, 95.5% of patients are still on RLAI. The mean PSP score significantly improved from 48.0 Ϯ 17.3 at baseline to 64.2 Ϯ 15.2 at 6 months (p < 0.001). Improvement in PSP was similar for patients hospitalized at baseline versus those who were ambulatory patients (PSP score increased by 17.2 and 16.1, respectively, p < 0.001 for both). Furthermore, significant improvement in PSP was seen as soon as the first assessment after RLAI treatment at three months. CON-CLUSION: These 6-month interim results indicate that personal and social functioning as measured by the PSP improved with risperidone long-acting injection treatment in patients with schizophrenia.
and health-related quality-of-life (HRQoL). METHODS: A naturalistic, prospective, multicentre cohort study, named COMETA, was begun in subjects aged 18-40 years, diagnosed with schizophrenia or schizophreniform disorder 10 years before the enrolment. Subjects were enrolled and observed for up to 52 weeks in psychiatric centres throughout Italy. Sociodemographic, clinical, HRQoL and data on resource use were collected. RESULTS: Six-hundred-sixty-one patients (mean age 31.1 + 5.6, 65.4% male) with schizophrenia (86.5%) or schizophreniform disorder (13.5%) were enrolled in 86 centres during 2006-2007. Most patients had primary/lower secondary level education (51.9%), and were single (85.9%). A total of 56.6% of the subjects received help for their disease from relatives/friends, 37.3% of patients were employed, 10.3% were students. The PANSS (Positive and Negative Syndrome Scale) mean + SD score was 86.1 + 27.4. The CGI-S (Clinical Global Impression Severity) mean + SD score was 4.27 + 1.1, the GAF (Global Assessment of Functioning) mean + SD score was 54.3 + 13.8. Ninety days prior, patients were treated with olanzapine (32.5%), risperidone (31.5%), haloperidol (18.3%), aripiprazole (14.4%), quetiapine (12.4%) and clozapine (11.2%). Thirty percent of the patients took >2 different drugs (up to 5) in that period. Regarding HRQoL, 68.7% of patients reported problems on the anxiety/depression-domain of the EQ-5D, 52.3% on usual activities, 37.7% on pain/discomfort, 21.4% on mobility and 16.8% on self-care. The EQ-5D Visual Analogue Scale score was 63.6 + 17.8 (mean + SD). The SF-36 Physical-Summary-Score was 47.3 Ϯ 9.4 and the Mental Summary Score was 39.0 Ϯ 9.6. CONCLUSION: Improvement of patients' well-being is an important objective of antipsychotic treatment. Baseline characteristics of this schizophrenic cohort show that there is ample space for improvement. Future analyses will focus on the relationship between adherence with therapy, symptomatology, costs, and quality of life.
PMH60 HEALTH STATUS AND WORK-RELATED OUTCOMES OF PATIENTS WITH ANXIETY DISORDERS AND DEPRESSION
Erickson S, Guthrie S, Abelson J University of Michigan, Ann Arbor, MI, USA OBJECTIVE: To determine the association between various levels of comorbid anxiety and depression with health-related quality of life and work-performance. METHODS: Patients from an anxiety disorders program clinic completed the SF-36, Work Limitations Questionnaire, Work Productivity and Activity Impairment Questionnaire, Endicott Work Productivity Scale, and Work Performance Scale. The Beck Anxiety Inventory (BAI) and the Beck Depression Inventory (BDI) were used to determine the severity of anxiety and depression, respectively. Patients were categorized as lowBAI/lowBDI, highBAI/lowBDI, highBAI/ lowBDI, and highBAI/highBDI. The influence of severity of anxiety/depression on the eight SF-36 scales, the SF-36 PCS and MCS, and each work-performance instrument scale score was determined using ANOVA with Scheffe post-hoc analyses. Multivariate linear regression assessed the combined association of BAI and BDI on SF-36 and work-performance scales, controlling for patient demographics. P values of <0.05 were statistically significant. RESULTS: Ninety-one patients provided complete SF-36, BAI and BDI. Of these, 61 were employed. There were no differences in demographics between groups. Post-hoc analysis indicated that lowBAI/lowBDI patients had significantly higher MCS (41.2 + 10.9) compared to highBAI/lowBDI (MCS = 29.9 + 8.3), lowBAI/highBDI (MCS = 23.7 + 15.8), and highBAI/highBDI (MCS = 17.4 + 9.9). The difference between highBAI/lowBDI and lowBAI/highBDI were not signifi-Abstracts A127 cant. HighBAI/highBDI was significantly different than the other groups (p < 0.01). This pattern was similar for social function, role emotion, mental health. Physical-related SF-36 domains were generally not different between groups. The difference in work-performance scale scores followed the same general pattern of less impairment with lowBAI/lowBDI (for example, WPAI-Percent Impairment While Working scale 0.22 + 0.3) and highBAI/highBDI (WPAI Percent Impairment While Working 0.77 + 0.2), p < 0.01. Other work scales followed a similar pattern. BDI routinely was more significant in regression models compared to BAI. CONCLUSION: Comorbid anxiety and depression greatly impair patients. Clinicians and researchers should measure the presence and severity of both mental illnesses when assessing their influence on health-related quality of life and work-performance.
PMH61 PATIENT PREFERENCES IN THE THERAPY OF ADHD-A DISCRETE CHOICE EXPERIMENT
Mühlbacher AC 1 , Rudolph I 2 , Lincke HJ 1 , Nübling M 1 1 Gesellschaft für empirische Beratung mbH, D-79211 Denzlingen, Germany, 2 Janssen Cilag GmbH, Neuss/Germany, D-41470 Neuss, Germany OBJECTIVE: While the clinical efficacy of drugs for ADHD is widely studied in clinical trials (usually randomised controlled trials, RCTs), patient preferences with regard to their treatments are not well understood and therefore considered to a less extent. Aim of this study therefore was to explore the patients' perceptions of an "ideal treatment" for ADHD. METHODS: Examination of the state of the art as reported in the literature was followed by a qualitative study with four focus groups consisting of 6-8 parents of ADHD-patients each. In a subsequent quantitative study phase, data was collected in an online or paper-pencil self-fill-in questionnaire for parents of patients and patient (age >14 years) themselves. It included sociodemographic data, treatment history and actual treatment and patients' preferences of therapy characteristics using direct measurement (23 items on a 5-point Likert-scale) as well as a discrete-choice-experiment (DCE, 8 pairs with 6 characteristics). RESULTS: N = 213 questionnaires were filled; most of them by the parents of patients (79% by the mothers, 9% by the fathers). Most of the patients were male (83%) and most of them (83%) had actual medical treatment of ADHD. Direct measurement showed "good emotional quality of live", "no addiction on medication", "improvement of concentration capability," and "few side effects" in the first places. In the DCE, alternatives with "better social quality of life (friendships etc. possible)", "better emotional quality of life (disease not all of the time mentally present)", and "longer duration of medication effect" were more likely to be chosen, giving thus similar results. CONCLUSION: This unique study demonstrates that it is possible to obtain valid and robust information from patients on what constitutes relevant patient outcomes. Such information should play a critical role in appraisal of treatment alternatives by HTA bodies.
PMH62 ASSESSING THE VALIDITY OF DERIVING CLINICAL DEMENTIA RATING (CDR) GLOBAL SCORES FROM INDEPENDENTLY OBTAINED FUNCTIONAL RATING SCALE (FRS) SCORES IN VASCULAR DEMENTIA AND MIXED VASCULAR DEMENTIA PATIENTS
Lanctôt KL 1 , Herrmann N 1 , Hsiung GYR 2 , Masoud ST 1 1 Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2 University of British Columbia, Vancouver, BC, Canada OBJECTIVE: The functional rating scale (FRS) and clinical dementia rating (CDR) scale are two different tests used to assess the severity and progression of dementia. Although the FRS covers more domains and requires less time to administer than the CDR, the CDR categorizes severity of dementia while the FRS does not. The purpose of this research was to calculate the agreement between the FRS and CDR scales and to determine if they could be used interchangeably for diagnosis of disease severity in vascular dementia (VaD). METHODS: Inpatients and outpatients diagnosed with VaD/mixed VaD were evaluated using the FRS and CDR scales. The tests were administered independently by two separate raters. Since the FRS contains all of the domains that are rated in the CDR, CDR scores were extracted from the corresponding FRS domains and used to derive global scores of severity. FRS-derived global scores were then compared to original CDR global scores by a weighted kappa analysis to measure concordance. RESULTS: A total of 28 VaD/mixed VaD patients were involved in the study. In the patient population, 60.7% were males and average age was 78.6 Ϯ 7.7 years. Average MMSE score was 19.9 Ϯ 4.8 while mean Hachinski score was 8.1 Ϯ 2.8. The modal value obtained for both the FRS-derived CDR scores and original CDR scores was 2; in both groups scores ranged from 0.5-3 with 43% of patients diagnosed in category 2 (moderate dementia). The weighted kappa analysis showed substantial concordance (kappa = 0.75) between FRSderived CDR and original CDR-global scores. CONCLUSION: These results suggest that FRS scores can be used to derive global scores that are in agreement with those produced by the validated CDR method. This serves as a powerful tool since it allows for easy comparison of the diagnostic distribution, natural history and treatment outcomes of individuals with dementia.
PMH63 PATIENT REPORTED MEASURES AS QUALITY ASSURANCE TOOLS IN CNS CLINICAL TRIALS
Daniel DG 1 , Friedmann B 2 , Butler A 3 1 United BioSource Corporation, McLean, VA, USA, 2 UnitedBiosource Corporation, Wayne, PA, USA, 3 United BioSource Corporation, Wayne, PA, USA OBJECTIVE: Signal detection and, ultimately, regulatory approval depend on high-quality, valid and reliable data. The subjective rating scales utilized in CNS clinical trials may be vulnerable to spurious ratings and intentional or unintentional manipulation of ratings by investigators at screening or baseline visits. The objective of this study was to evaluate the feasibility of utilizing a patient reported outcome as a quality assurance measure for evaluation of the quality of a clinician rated primary efficacy measure in a CNS clinical trial. METHODS: A proprietary ratings surveillance system was utilized in a multi-center, double blind, randomized, placebo-controlled clinical trial in which the Hamilton Anxiety Rating Scale (HARS) was the primary efficacy measure. The patient rated Beck Anxiety Inventory (BAI) was added to the baseline visit for quality assurance purposes. Based on published guidelines of the expected relationship between HARS and BAI scores, a computer program flagged aberrant ratings and three flags with the same rater triggered a teaching intervention. The ratings surveillance system was intended both to detect aberrant rating patterns and to deter intentional inflation of ratings in order to qualify subjects. RESULTS: The clinical trial is ongoing. 91 pairs of HARS and BAI ratings have been examined from the randomization visit. 61/91 (67%) pairs were flagged for discordance, in most cases (79%) due to disproportionately high HARS scores compared to the BAI. In 8 cases, the BAI was under 10 with the HARS 22 or greater. In 11 cases, there were at least 3 flags for the same rater and the pattern of discordance was considered to be of sufficient clinical significance to warrant a teaching intervention. CONCLUSION: Use of
